Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of
tumor cells by blocking the enzymes necessary for their growth.